Oxytocin: research
A hormone used during childbirth; nasal social and weight-loss benefits remain unproven.
Also called: Pitocin, Syntocinon, OT, OXT, TTA-121.
Neuropeptides · Oxytocin-receptor agonist and uterotonic hormone · Evidence: Approved drug.
A 2011 review covered 38 separate nasal-spray trials. This is a minimum count that leaves out later research and childbirth trials.
Studies
- Preventing bleeding after birth. meta-analysis, n=10018, Women having vaginal births. Preventive oxytocin reduced bleeding versus placebo or no uterotonic. (source)
- Cochrane update: 122 birth trials. meta-analysis, n=121931, Women having vaginal or caesarean births. The updated birth-prevention review supports oxytocin as a standard comparator. (source)
- Trust in a laboratory game. rct, Healthy male volunteers. A laboratory trust effect helped launch social-cognition research. (source)
- Adults with autism: 6 weeks. rct, n=19, Adults with autism. Primary outcomes were negative; some secondary measures improved. (source)
- Adult autism crossover: 6 weeks. crossover-rct, n=20, Adult men with autism. A small crossover trial found better social-reciprocity scores. (source)
- Autism dose finding: 16 or 32 IU/day. rct, n=60, Adolescents and young adults with autism. Neither dose improved the overall trial population. (source)
- Adult autism: 106 participants. rct, n=106, Adults aged 18–48 with autism. The primary social outcome did not improve versus placebo. (source)
- TTA-121: four nasal regimens. crossover-rct, n=109, Adult men with autism. The full analysis did not establish benefit at any tested regimen. (source)
- Adolescent autism: 8 weeks. rct, n=50, Boys aged 12–18 with autism. Repeated dosing did not improve measured social outcomes. (source)
- Young children: gradual nasal start. crossover-rct, n=31, Young children with autism. A small early study reported improved caregiver ratings. (source)
- Children: biomarker-adjusted pilot. rct, n=32, Children aged 6–12 with autism. The social signal depended on a biomarker-adjusted analysis. (source)
- SOARS-B: 24 weeks. rct, n=290, Children and adolescents aged 3–17 with autism. The largest pediatric trial found no social or cognitive benefit. (source)
- Young children: 12 weeks. rct, n=87, Children aged 3–12 with autism. The full sample showed no social benefit versus placebo. (source)
- Autism review: publication bias. meta-analysis, Autistic participants in controlled studies. The small pooled social effect was sensitive to publication bias. (source)
- Autism dose-response review. meta-analysis, n=498, Participants with autism in 12 RCTs. Exploratory dose signals did not establish an effective regimen. (source)
- Autism review: 733 participants. meta-analysis, n=733, Children and adults with autism in 12 RCTs. The 2026 review found no significant overall social benefit. (source)
- Mental-health trials: 2026 review. meta-analysis, n=1922, People with autism, schizophrenia, substance-use or other mental disorders. The overall mental-health benefit was not significant. (source)
- Obesity: early 20-person pilot. rct, n=20, Adults with obesity. A striking early weight-loss result was not reproduced in the larger trial. (source)
- One nasal dose before breakfast. crossover-rct, n=25, Healthy men across the weight range. A single dose reduced one meal, without showing sustained weight loss. (source)
- Food-intake review: 12 trials. meta-analysis, n=423, 266 nonpsychiatric and 157 psychiatric participants. Acute meal effects did not establish a long-term weight benefit. (source)
- Obesity: larger 8-week trial. rct, n=61, Adults with obesity. The same regimen as the early pilot did not reduce body weight. (source)
- Reproductive hormones: 2026 analysis. rct, n=61, Adults from the 61-person obesity trial. Eight weeks did not alter measured reproductive hormones. (source)
- Hypothalamic obesity: crossover pilot. crossover-rct, n=13, Ages 10–35 with obesity after hypothalamic/pituitary tumors. No significant weight benefit was detected. (source)
- Obesity: intravenous meal study. crossover-rct, n=24, Adults with obesity. A high blood exposure from an infusion did not reduce food intake. (source)
- Nasal versus intravenous exposure. pk-study, n=24, Healthy adults; 24 in the nasal/IV comparison. Very little nasal drug reached the blood, with large person-to-person variation. (source)
- Under-the-skin dose: local heat pain. crossover-rct, n=20, Healthy adults; 20 enrolled and 18 completed. A tiny local injection affected heat pain, not general social or mood outcomes. (source)
- Local injection before surgery. rct, n=30, Adults having laparoscopic gallbladder surgery. A small local-pain trial cannot establish a systemic injection dose. (source)
- Historical daily injection trial. rct, n=45, Breastfeeding women with breast engorgement. A historical daily regimen had uncertain benefit and weak safety reporting. (source)
- Sexual experience in 29 couples. crossover-rct, n=58, Healthy heterosexual couples. The study did not show better sex drive, erections or lubrication. (source)
- Prader-Willi: higher-dose crossover. crossover-rct, n=30, Ages 12–30 with Prader-Willi syndrome. Higher doses increased temper outbursts without useful overall benefit. (source)
- Prader-Willi infants: dose finding. open-label, n=18, Infants under 6 months with Prader-Willi syndrome. Early feeding improvements needed confirmation in a controlled trial. (source)
- Prader-Willi: 8-week pilot. rct, n=23, Children and adolescents with Prader-Willi syndrome. Placebo improved eating scores more than oxytocin. (source)
- Prader-Willi: 3-month crossover. crossover-rct, n=26, Children aged 3–11 with Prader-Willi syndrome. Overall results were negative; subgroup findings remain unconfirmed. (source)
- Early infant exposure: later follow-up. cohort, n=34, Children aged 3–4 previously exposed or unexposed as infants. A small follow-up did not find a primary communication benefit. (source)
- Prader-Willi infants: phase 3. rct, n=52, Infants under 3 months with Prader-Willi syndrome. The primary endpoint failed; a swallowing measure improved. (source)
- FOXY: intermittent dosing in dementia. crossover-rct, n=94, Adults aged 30–80 with frontotemporal dementia and apathy. Intermittent dosing produced a small reduction in dementia-related apathy. (source)
- Nasal safety: 38 early RCTs. systematic-review, n=1529, Research participants; 79% male. Short controlled studies were reassuring, but did not establish chronic safety. (source)
- Nasal safety in older adults. systematic-review, n=331, Adults aged 60+ across 9 RCTs. Short-term data do not resolve long-term safety in older adults. (source)
- Autism: small phase 3 registry report. open-label, n=7, Adolescents and adults with autism. A phase label does not overcome an uncontrolled seven-person study. (source)
- Prader-Willi dysphagia: results missing. rct, n=25, Children and adolescents with Prader-Willi syndrome. The completed phase 2/3 record had no posted results. (source)
- Prader-Willi adults: results missing. rct, n=50, Adults with Prader-Willi syndrome. The completed phase 2/3 record had no posted results. (source)
- Autism mirror-system study: results missing. crossover-rct, n=25, Autistic adults in the completed registry record. The completed registry-labelled phase 3 study had no posted results. (source)
- Autism: weight-based dose-finding pilot. open-label, n=15, Children and adolescents with autism and verbal IQ at least 70. The early weight-based pilot established only limited short-term tolerability. (source)
- On-tongue spray: social-cue responses. rct, n=80, Healthy adult men; 80 in the lingual trial. A laboratory task showed route-dependent responses, not a clinical treatment benefit. (source)
- Medicated lollipop: attention task. rct, n=72, Healthy adult men; 72 recruited. Mouth exposure altered a laboratory attention task; clinical benefit was not tested. (source)
- Vaginal gel: 8-week trial. rct, n=96, Postmenopausal women with vaginal atrophy. One small vaginal trial found local changes; these do not support nasal or injected libido dosing. (source)
- Vaginal gel: 2-week trial. rct, n=50, Postmenopausal women with vaginal atrophy. A short local study cannot establish a dose for other routes. (source)
- Trust findings: critical review. review, Human social-trust experiments. Oxytocin does not reliably increase human trust. (source)
- Autism: every-other-day dose plus play. crossover-rct, n=46, Children aged 3–8 with autism; 46 enrolled and 41 completed. A small combined drug-and-social-interaction pilot found improved scores. (source)
Oxytocin dosage
Typical reported dose: 25–100 mcg per injection, timing varies
- Pitocin: supervised labour infusion: Start 0.5–1 mU/min; increase by 1–2 mU/min every 30–60 minutes to the desired contraction pattern., then At 5–6 cm dilation, the rate may be reduced by similar increments. continuous infusion; adjust every 30–60 minutes, into a vein. Drug label. Studied in: Hospital obstetric patients. (source)
- Pitocin: bleeding after birth, IV: 10–40 units added to the running IV fluid; maximum 40 units per 1000 mL. Adjust rate to control uterine atony. continuous infusion adjusted to uterine response, into a vein. Drug label. Studied in: Hospital postpartum patients. (source)
- Pitocin: bleeding after birth, IM: 10 units (1 mL) intramuscularly after delivery of the placenta. one dose after delivery of the placenta, into muscle. Drug label. Studied in: Postpartum patients after placental delivery. (source)
- Pitocin: infusion after curettage: 10 units in 500 mL physiologic saline or 5% dextrose-in-water to support uterine contraction after curettage. infusion; rate individualized, into a vein. Drug label. Studied in: Patients after curettage for incomplete, inevitable or elective abortion. (source)
- Pitocin: midtrimester abortion infusion: 10–20 milliunits/minute; total dose must not exceed 30 units in 12 hours. continuous infusion; total capped over 12 hours, into a vein. Drug label. Studied in: Patients after intra-amniotic treatment for midtrimester abortion. (source)
- WHO: prevent bleeding after birth: 10 IU intramuscularly for postpartum-haemorrhage prevention. one preventive dose, into muscle. Clinician-published. Studied in: Women giving birth under skilled care. (source)
Highest studied: Highest located daily human regimen: 2.5 IU/day, about 4.2 mcg, in a weak 1953 engorgement trial..
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Oxytocin side effects and risks
Reported side effects
- Nasal discomfort or irritation: 8 week obesity trial: 6/31 (19.4%) vs 2/30 (6.7%) placebo., mild. Report persistent irritation or nosebleeds; review the formulation and delivery device. (source)
- Drowsiness: Single dose meal trial: 6/25 oxytocin sessions vs 4/25 placebo sessions., mild. Avoid driving if sleepy; severe sedation needs review. (source)
- Stomach or bowel symptoms: Obesity trial organ class events: 5/31 (16.1%) vs 8/30 (26.7%); not a rate for nausea alone., moderate. Review persistent nausea, vomiting or bowel symptoms with a clinician. (source)
- Restlessness or behaviour changes: SOARS B: restlessness 8% vs 2% placebo; increased appetite 16% vs 10%., moderate. Stop escalation and review agitation, aggression or sleep changes. (source)
- Headache: One moderate headache among 31 oxytocin participants in the obesity trial; overall headache rate unavailable., moderate. A severe headache with confusion, vomiting or weakness needs urgent assessment. (source)
- Low sodium or water intoxication: Seizures, coma and deaths are reported with prolonged high dose IV infusion; rates are unknown., serious. Stop exposure and get emergency care for confusion or seizures. (source)
- Fast heart rate (UK IV product): UK IV label: tachycardia is common (≥1/100 to <1/10). This is not a nasal use frequency., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
- Slow heart rate (UK IV product): UK IV label: bradycardia is common (≥1/100 to <1/10). This is not a nasal use frequency., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
- Abnormal heart rhythm (UK IV product): UK IV label: arrhythmia is uncommon (≥1/1,000 to <1/100). This is not a nasal use frequency., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
- Low blood pressure (UK IV product): UK IV label: hypotension has unknown frequency. This is not a nasal use frequency., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
- High blood pressure (US Pitocin injection): US Pitocin injection label reports high blood pressure without a rate; the nasal use rate is unknown., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
- Excessive uterine contractions or rupture: Reported in pregnancy and birth care; excessive dosing or a sensitive/scarred uterus raises risk., serious. Hospital staff stop the infusion for excessive contractions or a baby in distress. (source)
- Severe allergic reaction: unknown, serious. Call emergency services for swelling, breathing trouble or collapse. Latex allergy may increase risk. (source)
- Temporary breast enlargement: One oxytocin participant in the 106 person adult autism trial., moderate. Review new breast changes or discharge. (source)
Stop and get help if
- Confusion, severe headache, repeated vomiting, a seizure or unusual drowsiness: Stop oxytocin and get urgent care for possible low sodium or water intoxication.
- Chest pain, fainting, severe breathlessness or a racing/irregular heartbeat: Stop oxytocin and seek emergency care.
- Swollen tongue or face, hives with breathing trouble, or collapse: Call emergency services for a possible severe allergic reaction.
- Severe pelvic pain, nonstop contractions or heavy vaginal bleeding: Seek emergency obstetric care, especially if pregnancy is possible.
Who should avoid it
- pregnant: Unsupervised use in pregnancy risks uterine contractions and fetal harm. Hospital birth care is a separate approved indication with medical monitoring.
- breastfeeding: Obstetric use and supervised lactation research are separate; this is not a claim of proven infant toxicity.
- tryingToConceive: Precaution for use on your own: fertility and early-pregnancy safety are unknown.
- under18: Pediatric studies are evidence records and do not authorize home use.
- hormoneSensitiveCancer: Precaution outside birth care: long-term cancer and fertility safety are unknown. Hormone-sensitive cancer is not a labelled contraindication.
- other: Known allergy to oxytocin or its ingredients is a label contraindication.
- other: Latex allergy has been linked to anaphylaxis after oxytocin; alert the clinical team.
- other: Water retention can worsen it.
- other: Labels rule out labour use with unsafe vaginal birth, excessive contractions, obstructed labour or a baby in distress.
- other: A prior caesarean or major surgery on the uterus or cervix raises the risk of the uterus tearing during labour infusion.
- heartCondition: Blood pressure, heart rhythm and coronary blood flow can change. Long QT is a specific concern.
- uncontrolledBloodPressure: Severe blood-pressure changes have occurred with injected oxytocin and interacting drugs.
- kidneyDisease: Severe kidney impairment can increase water retention and possible oxytocin accumulation.
- seizureDisorder: Low sodium can cause seizures. A possible seizure also led to withdrawal from a small autism trial.
- psychiatricCondition: Agitation, aggression and temper outbursts have occurred. Nasal oxytocin is not an established mood or anxiety treatment.
- eatingDisorderHistory: Precaution: an eating-disorder history blocks appetite-suppression and fat-loss use. This is not a labelled contraindication.
- surgeryPlanned: Tell the anaesthesia team about use. Anaesthetics, vasoconstrictors and other uterotonics can change oxytocin effects.
- testedAthlete: Oxytocin is not specifically prohibited in the 2026 list. IV volume rules and other ingredients in a combination still matter.
- other: The UK IV product label contraindicates oxytocin within 6 hours after vaginal prostaglandins. This block requires both the vaginal exposure and the timing condition.
- other: Pitocin's boxed warning says it is not for starting labour without medical reasons. Benefits versus risks remain unknown.
Interactions
- Other oxytocin products and uterotonics: Combining these drugs may add to contraction and circulation effects. Use during childbirth needs specialist care.
- Prostaglandins used in obstetrics: Prostaglandins and their analogues can strengthen uterine contractions with IV oxytocin. The separate block applies within 6 hours after vaginal use.
- Drugs that prolong QT: Oxytocin can cause an irregular heartbeat. Drugs that delay the heart's electrical recovery, called QT prolongation, add risk.
- Vasoconstrictors and sympathomimetics: Oxytocin may further raise blood pressure. Severe increases were reported after a vasoconstrictor was used with an anaesthetic block near the tailbone.
- Inhaled anaesthetics: These drugs can weaken uterine contractions and cause unexpected blood-pressure changes or irregular heartbeats with oxytocin.
- Desmopressin and other water-retaining drugs: Water-retaining effects may add. A hypothalamic-obesity trial checked sodium and adjusted desmopressin; it did not prove a safe combination.
- Insulin and sulfonylureas: One acute study changed insulin sensitivity. A clinical interaction or added low-sugar rate has not been established.
Product quality risks
- A review of 559 nonrandomly sampled oxytocin products in 15 lower-income countries found 36% outside the 90–110% content specification.
- Those findings concerned medical supply chains; they do not estimate failure rates for online peptide vials.
- Poor cold-chain control can lower oxytocin content and increase breakdown products. Storage rules depend on the exact product.
- Compounded or unregulated preparations can have wrong strength or contamination; a purity percentage does not prove sterility.
How Oxytocin works
Oxytocin makes the uterus contract. It also affects brain signals linked to social attention and appetite. Nasal sprays have no reliable bonding or calming benefit.
- Oxytocin receptor: Raises calcium inside uterine muscle cells, causing contractions.
- Brain oxytocin signalling: Can change social attention and food-related responses; clinical benefits are inconsistent.
- Water balance: At high exposure, it can retain water and lower blood sodium.
Half-life: Pitocin label: blood levels halve in about 1–6 minutes. This does not measure nasal effect duration.
Gaps: The humanStudies value is a verified floor of 38 distinct early nasal RCTs. The full number of unique human trials is unknown. PubMed returned 1372 human clinical-trial records with oxytocin in the title through October 18, 2026; reports and trials are not interchangeable. A registry intervention search returned 935 records, including 515 completed interventional records; this includes comparators, related work and duplicate publications. Oral research used on-tongue sprays or medicated lollipops; efficacy and dose conversion for marketed sublingual products remain unestablished. No replicated nasal dose, cycling schedule or titration is established for bonding, stress, sleep or general weight loss. Community frequency labels describe this small search sample. They are not survey estimates of how many people use oxytocin. No repeated systemic subcutaneous study supporting 25–100 mcg for mood, bonding or sleep was located; small local-pain studies do not fill that gap. The exact per-arm numeric outcomes and adverse-event rates were unavailable in some retrieved abstracts; they were not guessed. Long-term fertility, cancer, cardiovascular, behavioural and nasal-formulation safety remain unresolved. No formal interaction studies with common anticoagulants or most chronic medicines were found. A missing interaction is not proof of compatibility. The schema has no intravaginal route. Vaginal-gel studies were searched but no vaginal protocol was forced into the topical route. No systematic independent testing of online oxytocin powder vials or oxytocin-specific counterfeit-pen series was located. No validated home-powder diluent, spray calibration, sterility method or shelf life was located. No oxytocin-specific final 503A/503B inclusion decision or PCAC vote was located. Component status and Category 1 nomination do not approve nasal products. Country-specific possession/import rules and every EU national nasal product were not fully resolved. Registry-labelled phase 3 includes small or unpublished studies. Carbetocin phase 3 results concern a different molecule and are not oxytocin evidence.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- PITOCIN- oxytocin injection, Par Health USA, LLC · DailyMed · 2026
- Search results summary, Health Canada · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Understanding the Risks of Compounded Drugs, FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Oxytocin 10 IU/ml Solution for infusion - Summary of Product Characteristics (SmPC), electronic medicines compendium · 2025
- Postpartum interventions to prevent postpartum haemorrhage, World Health Organization · 2025
- WHO recommendations on maternal and newborn care for a positive postnatal experience, World Health Organization · 2022
- Syntometrine, Phebra Pty Ltd · Australian Commission on Safety and Quality in Health Care · 2019
- PSUSA/00002263/201706 - periodic safety update report single assessment, EMA · 2018
- Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry, FDA · 2016
- Oxytocin (Aspen), Healthdirect Australia
- SYNTOCINON oxytocin 10 IU/1 mL injection ampoule (13383), Therapeutic Goods Administration
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.